Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Vorld Pharma | Ortojorjia | Kalandadze | SBC Global | Geo - Pharma |
|---|---|---|---|---|---|
| Total Revenue | 2,701 | 2,676 | 2,312 | 2,106 | — |
| Total COGS | -917 | -1,122 | -2,075 | -1,501 | — |
| Gross Profit | 1,785 | 1,554 | 237 | 605 | — |
| Gross Margin | 66.1% | 58.1% | 10.3% | 28.7% | — |
| Total Operating Expenses | -1,515 | -575 | -363 | -69 | — |
| EBITDA | 269 | 979 | -125 | 536 | — |
| EBITDA Margin | 10.0% | 36.6% | -5.4% | 25.4% | — |
| Total D&A | -35 | -17 | -14 | -11 | — |
| EBIT / Operating Income | 234 | 962 | -139 | 525 | — |
| Total Interest Expense | -131 | — | — | — | — |
| Profit Before Tax | 104 | 955 | -133 | 507 | — |
| Total Income Tax | 0 | 0 | -16 | 0 | — |
| Net Profit / (Loss) | 104 | 955 | -149 | 507 | — |
| Net Margin | 3.8% | 35.7% | -6.4% | 24.1% | — |
| Total Other Income | — | -7 | 6 | -18 | — |
Not every picked company reports every selected year — FY2024: no filing for Geo - Pharma. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Ortojorjia | Pharma | 36.6% | 86th pct | 110 |
| SBC Global | Pharma | 25.4% | 69th pct | 110 |
| Vorld Pharma | Pharma | 10.0% | 36th pct | 110 |
| Kalandadze | Pharma | -5.4% | 7th pct | 110 |
| Geo - Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.